NASDAQ$PBYI
Puma Biotechnology Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Puma Biotechnology reported a net loss for Q1 2020, with product revenue increasing slightly compared to Q1 2019.
Puma Biotechnology reported a net loss of $16.9 million, or $0.43 per share, for the first quarter of 2020. Net product revenue was $48.6 million, compared to $45.6 million in the first quarter of 2019. Total revenue for the first quarter of 2020 was $51.2 million, compared to $99.1 million for the first quarter of 2019.
- Net product revenue for Q1 2020 was $48.6 million, an increase from $45.6 million in Q1 2019.
- Puma reported a net loss of $16.9 million, or $0.43 per share, for Q1 2020, compared to a net loss of $10.1 million, or $0.26 per share, for Q1 2019.
- Non-GAAP adjusted net loss was $8.0 million, or $0.20 per share, for Q1 2020, compared to non-GAAP adjusted net income of $8.1 million, or $0.20 per share, for Q1 2019.
- Cash, cash equivalents and marketable securities totaled $100.6 million as of March 31, 2020.
Headline financials
Revenue & EPS history
Puma Biotechnology · Revenue · Quarterly
$51.2M
Revenue by segment
Puma Biotechnology · $49.2M total across 2 segments · Q1 2020
- Product Revenue, Net$48.6M—98.8%
- Royalty Revenue$600K—1.2%
Forward guidance
Puma anticipates several key milestones over the next 12 months, including a pre-NDA meeting with the FDA, reporting Phase II data from the SUMMIT trial, reporting additional data from the Phase II CONTROL trial, and receiving regulatory decisions for an extended adjuvant HER2-positive early stage breast cancer indication in additional countries.
Tailwinds
- Conducting a pre-NDA meeting with the FDA to discuss accelerated approval of neratinib in HER2 mutated hormone receptor positive breast cancer and HER2 mutated cervical cancer in the first quarter of 2021.
- Reporting Phase II data from the HER-positive breast and cervical cancer cohort from the SUMMIT trial of neratinib in patients with HER2 mutations in the fourth quarter of 2020.
- Reporting additional data from the Phase II CONTROL trial in the fourth quarter of 2020.
- Receiving regulatory decisions for an extended adjuvant HER2-positive early stage breast cancer indication in additional countries.
- Maintain a significant stock of NERLYNX and do not anticipate any disruption of supply to existing or new patients.
Headwinds
- Any adverse impact on Puma’s business or the global economy and financial markets, generally, from the global COVID-19 pandemic
- Risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements.
- These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors
- The risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time
- Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-1.6%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+4.4%
Avg return
30 days after
47%
21 / 45 earnings
Positive
+36.4%
Q4 2018
Best reaction
-45.8%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -6.0% | -5.8% | |
| Q4 2025 | -25.1% | -15.8% | -20.0% | |
| Q3 2025 | +21.8% | +1.8% | +8.2% | |
| Q1 2025 | -4.6% | -5.5% | +21.2% | |
| Q4 2024 | +19.7% | +18.4% | +5.0% | |
| Q3 2024 | -5.9% | +4.9% | +2.0% | |
| Q2 2024 | +6.7% | +12.3% | -30.4% | |
| Q1 2024 | -1.8% | -4.0% | -22.2% | |
| Q4 2023 | -10.8% | -21.5% | -19.7% | |
| Q3 2023 | +4.9% | +9.4% | +41.5% | |
| Q2 2023 | +5.8% | +13.3% | +2.5% | |
| Q1 2023 | +19.8% | +19.4% | +35.0% | |
| Q4 2022 | -20.1% | -26.6% | -23.1% | |
| Q3 2022 | +25.5% | +50.9% | +106.0% | |
| Q2 2022 | +23.5% | +17.4% | -17.0% | |
| Q1 2022 | -19.1% | -26.0% | -4.9% | |
| Q4 2021 | +13.5% | +25.7% | +34.2% | |
| Q3 2021 | -39.1% | -42.2% | -54.6% | |
| Q2 2021 | +3.6% | +3.6% | +7.9% | |
| Q1 2021 | +1.6% | -0.8% | +17.0% | |
| Q4 2020 | -11.9% | -11.9% | -12.6% | |
| Q3 2020 | -11.0% | +1.3% | +31.8% | |
| Q2 2020 | -5.7% | -7.9% | -11.6% | |
| Q1 2020 | +11.2% | +23.1% | +6.4% | |
| Q4 2019 | -2.4% | -18.8% | -43.9% | |
| Q3 2019 | +4.2% | +18.0% | +9.1% | |
| Q2 2019 | +26.7% | +25.8% | +22.1% | |
| Q1 2019 | -38.6% | -41.5% | -53.9% | |
| Q4 2018 | +36.4% | +35.3% | +35.9% | |
| Q3 2018 | -45.8% | -39.5% | -37.3% | |
| Q2 2018 | -7.5% | -7.1% | -2.1% | |
| Q1 2018 | -19.0% | -18.9% | -24.3% | |
| Q4 2017 | +8.7% | +16.7% | +4.1% | |
| Q3 2017 | -22.2% | -24.3% | -23.9% | |
| Q2 2017 | -11.6% | -1.7% | +28.0% | |
| Q1 2017 | +1.5% | +4.3% | +163.9% | |
| Q4 2016 | -10.6% | -8.3% | +1.4% | |
| Q3 2016 | +21.3% | -0.5% | -9.4% | |
| Q3 2015 | -9.6% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q1 2013 | +3.7% | — | — | |
| Q3 2012 | -6.4% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +1.9% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro